Here's a brief video I did for Swedish Medical Center that discusses the issue that a minority of lung cancers might not actually require intervention...
I just did a brief video that appears on my The Swedish hospital website/blog, addressing the question of why it is standard to give single agent but...
One of the current controversies in the field of lung cancer is whether we should be doing biopsies routinely when a patient develops progression of...
I've mentioned in posts in the past about the settings in which local therapy might be appropriate for someone even when we know the cancer is...
Here's a brief video I did for Swedish Cancer Institute that explains the basic concepts of maintenance therapy for advanced NSCLC. I hope it's...
Drs. Ross Camidge and Corey Langer describe their practice when patients with advanced NSCLC bring them the results of broad molecular marker testing.
[powerpress]
Drs. Nate Pennell, Mary Pinder, and Jack West discuss trials presented at ASCO 2013 testing the potential value of molecular marker testing to select optimal chemo for advanced non-small cell lung cancer (NSCLC).
[powerpress]
This is the first video in our series from a program filmed directly from ASCO 2013. Drs. Nate Pennell, Mary Pinder, and Jack West discuss the Biomarkers France trial of testing on a national scale for clinically relevant biomarkers in advanced non-small cell lung cancer (NSCLC).
[powerpress]
>> Discuss this GRACEcast Video in the GRACE Discussion Forums
Drs. Nate Pennell from Cleveland Clinic and Mary Pinder from Moffitt Cancer Center in Tampa, FL sat down with our own Dr. Jack West to discuss early impressions of some of the most provocative research presented at the American Society for Clinical Oncology (ASCO) Annual Meeting in Chicago in early June.
Here's a growing list of podcasts covering the topics they discussed:
Is it possible to test for biomarkers in lung cancer on a national scale?
Drs. Nate Pennell, Mary Pinder, and Jack West discuss the Biomarkers France trial of testing on a national scale for clinically relevant biomarkers in advanced non-small cell lung cancer (NSCLC).
[powerpress]
Dr. Greg Riely, from Memorial Sloan-Kettering, provides his perspective on the likelihood that molecular oncology principles and targeted therapies will become more broadly applicable for patients with squamous and other lung cancer subtypes.
[powerpress]
Dr. Geoffrey Oxnard, Dana Farber Cancer Institute, reviews his thought process in recommending a repeat biopsy after progression for patients with advanced lung cancer.
[powerpress]
Dr. Rosalyn Juergens, McMaster University, discusses the evidence and her personal interpretation and recommended approach to maintenance therapy for advanced non-small cell lung cancer.
[powerpress]
Dr. Sarah Goldberg from Yale Cancer Center describes which patients with advanced NSCLC she seeks molecular marker testing on.
[powerpress]
Dr. Ravi Salgia from the University of Chicago discusses the trend of patients consulting Dr.Google - finding information of varied quality on the internet.
[powerpress]
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.